FY2025 EPS Estimates for Vaxcyte Lowered by Leerink Partnrs

Vaxcyte, Inc. (NASDAQ:PCVX) – Equities research analysts at Leerink Partnrs reduced their FY2025 earnings per share estimates for shares of Vaxcyte in a report issued on Tuesday, November 4th. Leerink Partnrs analyst D. Risinger now expects that the company will earn ($6.36) per share for the year, down from their previous estimate of ($5.96). The consensus estimate for Vaxcyte’s current full-year earnings is ($4.21) per share. Leerink Partnrs also issued estimates for Vaxcyte’s Q4 2025 earnings at ($1.58) EPS, FY2026 earnings at ($6.65) EPS, FY2027 earnings at ($7.16) EPS, FY2028 earnings at ($6.98) EPS and FY2029 earnings at ($1.78) EPS.

Several other research analysts also recently commented on PCVX. Cowen reaffirmed a “buy” rating on shares of Vaxcyte in a report on Thursday, August 7th. The Goldman Sachs Group started coverage on Vaxcyte in a report on Friday, September 12th. They issued a “neutral” rating and a $38.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research note on Tuesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $106.25.

Vaxcyte Stock Up 3.4%

PCVX opened at $41.71 on Friday. The firm has a 50-day moving average price of $37.88 and a 200-day moving average price of $34.91. Vaxcyte has a twelve month low of $27.66 and a twelve month high of $107.31. The company has a market capitalization of $5.46 billion, a price-to-earnings ratio of -8.62 and a beta of 1.07.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.29). During the same quarter last year, the company posted ($0.83) earnings per share.

Hedge Funds Weigh In On Vaxcyte

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AlphaQuest LLC purchased a new stake in shares of Vaxcyte in the 1st quarter valued at about $33,000. BI Asset Management Fondsmaeglerselskab A S purchased a new position in shares of Vaxcyte during the first quarter worth about $35,000. IFP Advisors Inc increased its position in shares of Vaxcyte by 376.4% in the first quarter. IFP Advisors Inc now owns 1,653 shares of the company’s stock worth $62,000 after purchasing an additional 1,306 shares during the last quarter. CWM LLC raised its stake in Vaxcyte by 197.3% in the second quarter. CWM LLC now owns 1,680 shares of the company’s stock valued at $55,000 after purchasing an additional 1,115 shares in the last quarter. Finally, Advisors Asset Management Inc. lifted its position in Vaxcyte by 81.6% during the first quarter. Advisors Asset Management Inc. now owns 1,929 shares of the company’s stock valued at $73,000 after purchasing an additional 867 shares during the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.